Delivering unique therapeutic and R&D monoclonal antibodies against membrane receptors and haptens

SYnAbs generates innovative monoclonal antibodies against:

SYnAbs unique technologies (SYnDNA vector, SYnCell syngeneic cell, in-house adjuvant) coupled with its strong expertise in breaking immune tolerance in proprietary rat-LOU species, ensure the generation of high specificity and higher affinity antibodies, benefiting from natural in-vivo maturation and targeting epitopes that are difficult to express in their native and functionally active conformation.

 

The application of such technologies have led, among others, to the generation of numerous functional therapeutic antibodies like : 





Raising antibodies against difficult to express antigens


Generating antibodies against conformation sensitive targets thanks to proprietary DNA, conformational peptide and whole cell immunization technologies


>99% success rate for small and poor immunogenic antigens and highly homologous epitopes


Extreme specificity monoclonal antibodies


Higher affinity monoclonal antibodies


Access to multiple immune repertoires and benefiting from natural in-vivo maturation


Additional epitope recognition in proprietary rat-LOU




Where to meet SYnAbs in 2023?

 

Mar. 20th - Mar. 22nd

Apr. 14th - Apr. 19th

May 10th - May 12th

June 5th - June 8th

Oct 10th - Oct 12th

Oct 12th - Oct 14th

Oct 20th - Oct 24th

Nov 1st - Nov 5th

Nov 6th - Nov 8th 

Nov 14th - Nov 16th

Nov 15th - Nov 18th

Dec 12th - Dec 13th

 

 

BioEurope Spring, Basel

AACR, Orlando

Bio Korea, Seoul

BIO International, Boston

Festival of Biologics, Basel

BioJapan, Yokohama

ESMO, Madrid

SITC, San Diego

BioEurope Fall, Munich

PEGS

Medica

BioFIT

Download
SYnAbs ISO 9001 Certificate
Certificats Synabs 2021 (1).pdf
Adobe Acrobat Document 441.9 KB


Le Fonds européen de développement régional et la Wallonie investissent dans votre avenir.

http://europe.wallonie.be


MENAC - Modifications Epigénétiques des Nucléosomes Associés au Cancer

 

Le projet MENAC a pour objectif de développer de tests innovants non invasifs pour la détection précoce 

de différents types de cancers.

 

Ce projet réalisé en partenariat par les sociétés Volition et Synabs passe par la création d'anticorps monoclonaux 

et la mise au point de nouveaux immuno-essais diagnostiques et théranostiques.

 

Subvention de 1.990.798€

 


A flexible, cost-effective platform developed for the discovery of novel compounds (protein degraders)